04 August 2026
04 August 2026
One of the largest global pharma companies would be created if a deal were to materialise.
The companies anticipate closing the merger in H1 2027, pending regulatory clearances and approval from Lantheus’ shareholders.
Through this merger, the duo will combine their commercial medicinal portfolios, which span CNS and opioid use disorders (OUDs).
Amgen is investigating the extent of this breach, as preliminary findings reveal that it has exposed private patient and proprietary information.
The FDA's decision for olomorasib was based on preliminary findings from the Phase I/II LOXO-RAS-20001 trial.
IMPACT Therapeutics is set to receive an upfront payment, near-term regulatory milestones, and commercial milestone payments for sales.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
